Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS

TARGET: Targeted antibiotic therapy for high-risk children with watery diarrhoea and malnutrition

Descrizione del progetto

Una terapia mirata per la diarrea acquosa

Sebbene molti casi di diarrea acquosa acuta siano causati da batteri, l’Organizzazione mondiale della sanità sconsiglia l’uso sistematico di antibiotici. Il progetto TARGET, finanziato dall’UE, condurrà una sperimentazione clinica in Kenya e in Tanzania per valutare se un trattamento antibiotico mirato sia in grado di migliorare gli esiti clinici, per identificare i bambini che potrebbero trarne maggior beneficio e per valutare i rischi, compresa la resistenza agli antimicrobici, fornendo risultati che contribuiranno a definire le linee guida e le politiche dell’OMS per la gestione della diarrea. Migliorando l’assistenza ai bambini vulnerabili, TARGET si propone di ridurre la morbilità, la mortalità e i ricoveri ripetuti, anche in caso di future sfide climatiche, con l’obiettivo generale di migliorare la gestione della diarrea.

Obiettivo

BACKGROUND: Diarrhoea is an important cause of morbidity and mortality in children under 5, especially in SSA. WHO guidelines do not recommend antibiotics for acute watery diarrhoea, while 25-50% of watery diarrhoea episodes are caused by bacteria. Children with co-morbid malnutrition and watery diarrhoea are more likely to have bacterial aetiology and poor outcomes. We hypothesize that the benefits of appropriate antibiotic treatment for these children are greater than the associated risks.
AIM: TARGET aims to generate evidence on how improved management and treatment of watery diarrhoea in children with malnutrition can reduce childhood morbidity and mortality, and support implementation of this evidence across SSA, now and in a climate-uncertain future.
APPROACH: Central to our approach is a clinical trial evaluating the benefit of two antibiotic treatments for watery diarrhoea in children with malnutrition in Kenya and Tanzania. We will assess the characteristics of children who most benefit from therapy and estimate generalizability of the observed effects to other vulnerable populations and under future climate scenarios. We will evaluate the risk-benefit trade-off with the development of antimicrobial resistance and assess provider perspectives on antibiotic use and clinical guidelines. In our dissemination, we focus on uptake in WHO guidelines and policy translation. A critical focus of the project is the development of capacity for leadership of multisite clinical trials focused on enteric infections at KEMRI (Kenya) and HGHRI (Tanzania).
IMPACT: Our late-stage clinical data will directly inform guidelines for treating children with watery diarrhoea and malnutrition and contribute to timely identification of vulnerable children. This has potential to reduce childhood deaths and repeat hospitalization. Importantly, TARGET will contribute to leadership of our SSA partners in future clinical trials, funding applications, impactful research, and publications.

Campo scientifico (EuroSciVoc)

Parole chiave

Programma(i)

Argomento(i)

Meccanismo di finanziamento

HORIZON-JU-RIA - HORIZON JU Research and Innovation Actions

Vedi tutti i progetti finanziati nell’ambito di questo schema di finanziamento

Invito a presentare proposte

(si apre in una nuova finestra) HORIZON-JU-GH-EDCTP3-2025-04-two-stage

Vedi tutti i progetti finanziati nell’ambito del bando

Coordinatore

STICHTING AMSTERDAM UMC
Contributo netto dell'UE
€ 1 812 485,00
Costo totale
€ 1 812 485,00

Partecipanti (5)

Partner (3)